Novavax, swamped with FDA's manufacturing 'questions,' hopes for U.S. coronavirus shot trial by the end of the year

Novavax, swamped with FDA's manufacturing 'questions,' hopes for U.S. coronavirus shot trial by the end of the year

Source: 
Fierce Pharma
snippet: 

With two players in the race for a COVID-19 vaccine nearing the finish line on world-first regulatory approvals, Maryland biotech Novavax continues to lag behind in getting its candidate into a late-stage trial in the U.S. Now, that trial has been pushed back further as the FDA targets its manufacturing plans.